Truist Securities raises Genmab stock price target to $49 on Merus acquisition
PositiveFinancial Markets

Truist Securities has raised its price target for Genmab's stock to $49 following the company's acquisition of Merus. This move reflects confidence in Genmab's growth potential and strategic direction, which could lead to increased investor interest and a stronger market position. The acquisition is seen as a significant step in enhancing Genmab's portfolio and capabilities in the biotech sector.
— Curated by the World Pulse Now AI Editorial System